Bioventus (NASDAQ:BVS) Price Target Raised to $19.00

Bioventus (NASDAQ:BVS) had its price target raised by Canaccord Genuity Group from $15.00 to $19.00 in a report published on Monday, MarketBeat reports. They currently have a buy rating on the stock.

Several other brokerages have also recently weighed in on BVS. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 price target on shares of Bioventus in a research note on Monday. Barrington Research set a $18.00 price objective on Bioventus in a research note on Thursday, August 6th. Weiss Ratings upgraded Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, August 6th. Finally, Craig Hallum reissued a “buy” rating and set a $18.00 target price on shares of Bioventus in a research report on Thursday, August 6th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.80.

Bioventus Stock Performance

Shares of Bioventus stock opened at $14.68 on Monday. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of 19.07, a P/E/G ratio of 1.82 and a beta of 0.63. Bioventus has a twelve month low of $6.26 and a twelve month high of $15.89. The company’s fifty day moving average is $11.67 and its 200 day moving average is $10.05. The company has a quick ratio of 1.17, a current ratio of 1.69 and a debt-to-equity ratio of 0.83.

Bioventus (NASDAQ:BVS) last announced its earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.22. The business had revenue of $153.21 million during the quarter. Bioventus had a return on equity of 28.08% and a net margin of 9.36%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Sell-side analysts forecast that Bioventus will post 0.79 EPS for the current year.

Institutional Trading of Bioventus

Large investors have recently bought and sold shares of the business. Marshall Wace LLP lifted its stake in shares of Bioventus by 0.4% in the 4th quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock valued at $2,149,000 after purchasing an additional 1,281 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Bioventus by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after purchasing an additional 1,538 shares during the period. Mercer Global Advisors Inc. ADV grew its stake in Bioventus by 16.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock worth $101,000 after purchasing an additional 1,887 shares during the period. Deutsche Bank AG increased its holdings in Bioventus by 8.2% in the fourth quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock worth $187,000 after purchasing an additional 1,908 shares in the last quarter. Finally, Engineers Gate Manager LP increased its holdings in Bioventus by 6.0% in the fourth quarter. Engineers Gate Manager LP now owns 68,889 shares of the company’s stock worth $513,000 after purchasing an additional 3,909 shares in the last quarter. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non?surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low?intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.